테리바 바이올로직스(TOVX)는 NYSE MKT에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.23 (-0.87%), 시가총액 $0.01B, 52주 범위 $0.18 ~ $0.84.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematop
테리바 바이올로직스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
테리바 바이올로직스의 현재 주가는 $0.23 (-0.87%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
테리바 바이올로직스의 시가총액은 약 $0.01B입니다.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabi